Predictmedix AI Inc. (CSE:PMED, OTCQB:PMEDF) said its artificial intelligence (AI) product suite can now detect early signs of diabetes by analyzing subtle biological indicators often undetected by conventional methods.
Calling the achievement a technological milestone, the company said it is excited to introduce its diabetes screening solution to its comprehensive lineup of AI-powered healthcare offerings.
According to a 2021 study by the Indian Council of Medical Research, the country has an estimated 101 million people with diabetes and 136 million individuals with pre-diabetes.
“The company's newly introduced diabetes non-invasive screening solution harnesses the power of advanced AI algorithms to analyze a wide spectrum of pertinent data, encompassing blood flow patterns to monitor volumetric variation in blood circulation which changes with varying blood sugar levels,” the company said in a statement.
The significance of early diabetic screening is key and eases the burden on healthcare systems by mitigating the progression of diabetes-linked complications.
Predictmedix is an emerging provider of rapid health screening and remote patient care solutions globally.